Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects

Randomized,Open Label,Balanced,Two Treatment, Four Period, Two Sequence, Single Oral Dose, Crossover, Replicate Study Under Fasting Conditions to Test Within Subject Variability of 20mg ER Torsemide and Demadex Tablets in Healthy Adults

Sponsors

Lead Sponsor: Sarfez Pharmaceuticals, Inc.

Source Sarfez Pharmaceuticals, Inc.
Brief Summary

The study will evaluate the within-subject variability of 20mg ER torsemide as compared to 20mg IR torsemide (Demadex) in fully replicate double-crossover trial in healthy volunteers, who are consuming a high-salt diet (300 mmol/day). The study will also evaluate the effects of ER torsemide and IR torsemide on 24h sodium excretion and total urinary excretion.

Detailed Description

Immediate Release (IR) Torsemide is a highly effective natriuretic drug but its short duration of action is a major drawback, which allows significant post-dose sodium retention, and as consequence, limits salt loss in patients with heart failure, unless dietary salt intake is severely restricted. Extended Release (ER) torsemide is being developed to address the drawback by prolonging the duration of action to increase sodium excretion even in patients who consume high salt diet (300 mmol/day). In addition, IR torsemide induces large and abrupt urination that, in some patients, causes incontinence, and as a result, compliance becomes challenging. ER torsemide is formulated to cause robust but gradual urination over an extended period to reduce accidental wetting and improve compliance. In this study, ER torsemide is tested for within-subject variability in fully replicate design double-crossover trial in healthy volunteers who are on a 300 mmol/day sodium diet (high salt diet). The primary endpoint of the study is full pharmacokinetics measurements after a single dose of either ER torsemide or IR torsemide (Demadex). The secondary endpoints are 24h sodium excretion and total urinary excretion.

Overall Status Completed
Start Date 2017-06-19
Completion Date 2017-07-20
Primary Completion Date 2017-07-20
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Peak plasma concentration 24 hour
Total plasma concentration 24 hour
Urinary excretion 24 hour
Secondary Outcome
Measure Time Frame
Urinary sodium excretion 24 hour
Urine output 24 hour
Enrollment 24
Condition
Intervention

Intervention Type: Drug

Intervention Name: Demadex 20mg Tablet

Description: Immediate Release (IR) Torsemide

Arm Group Label: Demadex 20mg Tablet

Other Name: Torsemide

Intervention Type: Drug

Intervention Name: ER Torsemide 20mg Tablet

Description: Extended Release Torsemide 20 mg tablet given once daily

Arm Group Label: ER Torsemide 20mg Tablet

Other Name: ER Torsemide

Eligibility

Criteria:

Inclusion Criteria: - Healthy male or female, non-smoker, weight 50 kg for male and 45 kg for female, clinically acceptable laboratory profiles with ECG and chest X-ray performed within 6 months Exclusion Criteria: - participation in bioavailability/bioequivalence studies, - history of drug abuse or alcohol dependence, - history of allergies including drug allergies, - known hypersensitivity to Torsemide or related drugs, - presence of clinically significant disorder, - systolic blood pressure <90 mm Hg or > 140 mm Hg diastolic blood pressure, - history of incontinence, - positive urine drug screening etc.

Gender:

Male

Minimum Age:

18 Years

Maximum Age:

45 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Christopher Wilcox, MD, PhD Principal Investigator Georgetown University
Overall Contact Contact information is only displayed when the study is recruiting subjects.
Location
Facility: I.E.C. Consultants
Location Countries

India

Verification Date

2018-04-01

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Demadex 20mg Tablet

Type: Active Comparator

Description: Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients

Label: ER Torsemide 20mg Tablet

Type: Experimental

Description: ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Intervention Model Description: Fully Replicate double-crossover

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Congestive Heart Failure

Clinical Trials on Demadex 20mg Tablet